Sep 30, 2015
Our Jackass of the Week is Martin Shkreli.
Shkreli is a 32 year old hedge fund manager specializing in healthcare companies. Shkreli’s company, Turing Pharmaceuticals bought the rights to the toxoplasmosis drug Daraprim last month, and from his responses to the outrage it seems he is embracing his title as the most hated man, and the Blue Streak Science Jackass of the Week.
He’s taken to Twitter and hurled insults, calling people “morons”, criticizing Twitter itself by saying that it “seems to be a great medium for socialist and liberal rage”.
On 28 September he took to the news shows and argued that Daraprim was grossly underpriced. On Bloomberg he stated, “The price per course of treatment to save your life was only $1,000 and we know these days, [with] modern pharmaceuticals, cancer drugs can cost $100,000 or more, rare-disease drugs can cost half a million dollars.”
He seems outraged that the drug was affordable!
A reporter reminded him that the pill costs about $1 to manufacture.
Hillary Clinton tweeted: "Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on. -H"
Shkreli also has a checkered past with a previous company he was the CEO of...even alledgedly harassing the wife and children of former employee of that company. A sworn affidavit was submitted by this employee to the Supreme Court of the State of New York regarding the alleged harassment.
The PhD Movie 2: Still
In Grad School
This episode of Blue Streak Science Podcast comes to you from Sydney, New South Wales; Atlanta, Georgia; and Santa Rosa, California.